Literature DB >> 16096013

Sleeping beauty transposon-mediated gene therapy for prolonged expression.

Perry B Hackett1, Stephen C Ekker, David A Largaespada, R Scott McIvor.   

Abstract

The Sleeping Beauty (SB) transposon system represents a new vector for non-viral gene transfer that melds advantages of viruses and other forms of naked DNA transfer. The transposon itself is comprised of two inverted terminal repeats of about 340 base pairs each. The SB system directs precise transfer of specific constructs from a donor plasmid into a mammalian chromosome. The excision of the transposon from a donor plasmid and integration into a chromosomal site is mediated by Sleeping Beauty transposase, which can be delivered to cells vita its gene or its mRNA. As a result of its integration in chromosomes, and its lack of viral sequences that are often detected by poorly understood cellular defense mechanisms, a gene in a chromosomally integrated transposon can be expressed over the lifetime of a cell. SB transposons integrate nearly randomly into chromosomes at TA-dinucleotide base pairs although the sequences flanking the TAs can influence the probability of integration at a given site. Although random integration of vectors into human genomes is often thought to raise significant safety issues, evidence to date does not indicate that random insertions of SB transposons represent risks that are equal to those of viral vectors. Here we review the activities of the SB system in mice used as a model for human gene therapy, methods of delivery of the SB system, and its efficacy in ameliorating disorders that model human disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096013     DOI: 10.1016/S0065-2660(05)54009-4

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  57 in total

1.  Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells.

Authors:  Xin Huang; Kari Haley; Marianna Wong; Hongfeng Guo; Changming Lu; Andrew Wilber; Xianzheng Zhou
Journal:  Hum Gene Ther       Date:  2010-10-19       Impact factor: 5.695

2.  Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells.

Authors:  Xin Huang; Hongfeng Guo; Syam Tammana; Yong-Chul Jung; Emil Mellgren; Preetinder Bassi; Qing Cao; Zheng Jin Tu; Yeong C Kim; Stephen C Ekker; Xiaolin Wu; San Ming Wang; Xianzheng Zhou
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

3.  Endogenous transposases affect differently Sleeping Beauty and Frog Prince transposons in fish cells.

Authors:  Jose Braulio Gallardo-Gálvez; Teresa Méndez; Julia Béjar; M Carmen Alvarez
Journal:  Mar Biotechnol (NY)       Date:  2010-12-01       Impact factor: 3.619

4.  Targeted delivery of in situ PCR-amplified Sleeping Beauty transposon genes to cancer cells with lipid-based nanoparticle-like protocells.

Authors:  Kun Ma; Duo Fu; Dongli Yu; Changhao Cui; Li Wang; Zhaoming Guo; Chuanbin Mao
Journal:  Biomaterials       Date:  2017-01-02       Impact factor: 12.479

Review 5.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

6.  The piggyBac transposon holds promise for human gene therapy.

Authors:  Cédric Feschotte
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

7.  Prolongation of heart allograft survival after long-term expression of soluble MHC class I antigens and vIL-10 in the liver by AAV-plasmid-mediated gene transfer.

Authors:  A Doenecke; E Frank; M N Scherer; H-J Schlitt; E K Geissler
Journal:  Langenbecks Arch Surg       Date:  2008-03-06       Impact factor: 3.445

8.  An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer.

Authors:  Justin A Kenkel; William W Tseng; Matthew G Davidson; Lorna L Tolentino; Okmi Choi; Nupur Bhattacharya; E Scott Seeley; Daniel A Winer; Nathan E Reticker-Flynn; Edgar G Engleman
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

Review 9.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Authors:  Harjeet Singh; Helen Huls; Partow Kebriaei; Laurence J N Cooper
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 10.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.